Cas:1072944-57-0 3,8-Dibromo-6-chloroimidazo[1,2-a]pyridine manufacturer & supplier

Chemical Name:3,8-Dibromo-6-chloroimidazo[1,2-a]pyridine

CAS.NO:1072944-57-0

Synonyms:3,8-dibromo-6-chloroimidazo[1,2-a]pyridine

Molecular Formula:C₇H₃Br₂ClN₂

Molecular Weight:310.37300

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:17.30000

Exact Mass:307.83500

LogP:3.51270

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3,8-dibromo-6-chloroimidazo[1,2-a]pyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3,8-dibromo-6-chloroimidazo[1,2-a]pyridine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,8-dibromo-6-chloroimidazo[1,2-a]pyridine Use and application,3,8-dibromo-6-chloroimidazo[1,2-a]pyridine technical grade,usp/ep/jp grade.

Related News: The StartScore model was developed by the company��s in-house supply chain experts based on actual performance data. 3,8-Dibromo-6-chloroimidazo[1,2-a]pyridine manufacturer ��With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.�� 3,8-Dibromo-6-chloroimidazo[1,2-a]pyridine supplier Production of J&J’s vaccine at the Baltimore site was halted by U.S. authorities in April and J&J was put in charge of manufacturing at the plant. 3,8-Dibromo-6-chloroimidazo[1,2-a]pyridine vendor International Chemical Investors Group (ICIG) recently announced it has entered into a purchase agreement under which an affiliate of ICIG will acquire the pharmaceutical intermediates business from Genzyme Corporation. 3,8-Dibromo-6-chloroimidazo[1,2-a]pyridine factory International Chemical Investors Group (ICIG) recently announced it has entered into a purchase agreement under which an affiliate of ICIG will acquire the pharmaceutical intermediates business from Genzyme Corporation.